{
  "nctId": "NCT00955201",
  "briefTitle": "Exercise-facilitated Neurorehabilitation in Diabetic Neuropathy",
  "officialTitle": "Exercise-Facilitated NeuroRehabilitation in Diabetic Neuropathy",
  "protocolDocument": {
    "nctId": "NCT00955201",
    "filename": "Prot_SAP_ICF_000.pdf",
    "label": "Study Protocol, Statistical Analysis Plan, and Informed Consent Form",
    "date": "2009-10-01",
    "uploadDate": "2019-02-13T11:43",
    "size": 593208,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT00955201/document/Prot_SAP_ICF_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": true
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "FACTORIAL",
  "masking": "SINGLE",
  "enrollmentInfo": {
    "enrollmentCount": 45,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2010-01-14",
    "completionDate": "2014-11-14",
    "primaryCompletionDate": "2014-11-14",
    "firstSubmitDate": "2009-08-06",
    "firstPostDate": "2009-08-10"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Clinical diagnosis of type 2 diabetes mellitus\n* stable blood glucose control\n* clinical findings consistent with length-dependent sensorimotor polyneuropathy, stage N2a\n\nExclusion Criteria:\n\n* foot ulceration\n* unstable heart disease\n* co-morbid conditions limiting exercise\n* disorders of the central nervous system causing weakness or sensory loss\n* received treatment with medications known to have neuropathy as a prominent side effect including vincristine, vinblastine, cis-platin, and paclitaxel\n* medical conditions that may be associated with neuropathies such as alcoholism, liver disease, kidney disease, toxic exposure, vitamin deficiency, autoimmune disorders, cancer, or hypothyroidism",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "45 Years",
    "maximumAge": "80 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Sural Nerve Amplitude",
        "description": "Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.",
        "timeFrame": "Baseline, 12, and 24 weeks"
      },
      {
        "measure": "Sural Nerve Latency",
        "description": "Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.",
        "timeFrame": "Baseline, 12 wks, 24 wks"
      },
      {
        "measure": "Sural Nerve Conduction Velocity",
        "description": "Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.",
        "timeFrame": "Baseline, 12 wks, 24 wks"
      },
      {
        "measure": "Tibial Nerve Amplitude",
        "description": "Maximal responses were obtained using percutaneous electrical stimuli. Distal motor nerve evoked compound muscle action potential (CMAP) potentials were recorded from tibial and peroneal nerves.To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.",
        "timeFrame": "Baseline, 12 weeks, 24 weeks"
      },
      {
        "measure": "Tibial Nerve Latency",
        "description": "Maximal responses were obtained using percutaneous electrical stimuli. Distal motor nerve evoked compound muscle action potential (CMAP) potentials were recorded from tibial and peroneal nerves.To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.",
        "timeFrame": "Baseline, 12 weeks, 24 weeks"
      },
      {
        "measure": "Tibial Nerve Conduction Velocity",
        "description": "Maximal responses were obtained using percutaneous electrical stimuli. Distal motor nerve evoked compound muscle action potential (CMAP) potentials were recorded from tibial and peroneal nerves.To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.",
        "timeFrame": "Baseline, 12 weeks, 24 weeks"
      },
      {
        "measure": "Sensory Median Nerve Amplitude",
        "description": "Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.",
        "timeFrame": "Baseline, 12, and 24 weeks"
      },
      {
        "measure": "Sensory Median Nerve Latency",
        "description": "Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.",
        "timeFrame": "Baseline, 12wks, 24 wks"
      },
      {
        "measure": "Sensory Median Nerve Conduction Velocity",
        "description": "Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.",
        "timeFrame": "Baseline, 12 wks, 24 wks"
      },
      {
        "measure": "Sensory Ulnar Nerve Amplitude",
        "description": "Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.",
        "timeFrame": "Baseline, 12 wks, 24 wks"
      },
      {
        "measure": "Sensory Ulnar Nerve Latency",
        "description": "Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.",
        "timeFrame": "Baseline, 12 wks, 24 wks"
      },
      {
        "measure": "Sensory Ulnar Nerve Conduction Velocity",
        "description": "Maximal responses were obtained using percutaneous electrical stimuli. Sensory nerve action potentials were recorded from sural (antidromic), median (antidromic to second digit), and ulnar nerves (antidromic to fifth digit).To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.",
        "timeFrame": "Baseline, 12 wks, 24 wks"
      },
      {
        "measure": "Peroneal Nerve Amplitude",
        "description": "Maximal responses were obtained using percutaneous electrical stimuli. Distal motor nerve evoked compound muscle action potential (CMAP) potentials were recorded from tibial and peroneal nerves.To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.",
        "timeFrame": "Baseline, 12 wks, 24 wks"
      },
      {
        "measure": "Peroneal Nerve Latency",
        "description": "Maximal responses were obtained using percutaneous electrical stimuli. Distal motor nerve evoked compound muscle action potential (CMAP) potentials were recorded from tibial and peroneal nerves.To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.",
        "timeFrame": "Baseline, 12 wks, 24 wks"
      },
      {
        "measure": "Peroneal Nerve Conduction Velocity",
        "description": "Maximal responses were obtained using percutaneous electrical stimuli. Distal motor nerve evoked compound muscle action potential (CMAP) potentials were recorded from tibial and peroneal nerves.To minimize inter-examiner variability and maximize neurophysiologic test/retest reliability, the same experienced neurologist conducted all nerve conduction studies on days separate from all other testing activities. A dedicated TECA Synergy electromyograph system was used for all nerve conduction studies. The patients dominant side was chosen. In patients with definable differences between the two sides, the side with the most prominent clinical findings was chosen. In all cases, the same limb was used for all three (baseline, 12-weeks, 24-weeks) conduction studies.",
        "timeFrame": "Baseline, 12 wks, 24 wks"
      }
    ],
    "secondary": [
      {
        "measure": "Symptom-Limited TMT Blood Glucose Response",
        "description": "Changes in blood glucose in response to modified Bruce Protocol treadmill test (TMT)",
        "timeFrame": "Initial entry into study, 12 and 24 weeks"
      },
      {
        "measure": "Short Form-36V: Physical Component Score",
        "description": "The short form-36Veterans (SF-36V) health survey questionnaire was used to measure health-related quality of life. This survey is comprised of eight subscales and two overall component scores, all of which have demonstrated high levels of internal consistency and discriminate validity when administered to groups of medically stable individuals. Patient aggregate responses for the eight distinct summary subscales and two component scores were compiled as a percentage of total points possible using the RAND 36-item health survey table. Data shown are expressed as a percentage of total possible score ranging from 0%-100% with 100% considered relatively good health and 0% considered poor health. Physical Component scores reflect perceived changes in physical health relative to the previous year.",
        "timeFrame": "Initial entry into study, 12 and 24 weeks"
      },
      {
        "measure": "Voluntary Duration of Symptom-Limited TMT",
        "description": "Total time subjects voluntarily exercised while undergoing a modified Bruce Protocol treadmill test (TMT)",
        "timeFrame": "baseline, 12-wks, 24-wks"
      },
      {
        "measure": "Symptom-Limited TMT Maximum Heart Rate",
        "description": "Peak heart rate achieved while undergoing a modified Bruce Protocol treadmill test (TMT)",
        "timeFrame": "baseline, 12-wks, 24-wks"
      },
      {
        "measure": "Symptom-Limited TMT Maximum Systolic Blood Pressure",
        "description": "Peak systolic BP achieved while undergoing a modified Bruce Protocol treadmill test (TMT)",
        "timeFrame": "Baseline, 12-wk, 24-wk"
      },
      {
        "measure": "Symptom-Limited TMT Maximum Minute Ventilation (VE)",
        "description": "Peak volume of air exchanged per minute achieved while undergoing a modified Bruce Protocol treadmill test (TMT)",
        "timeFrame": "Baseline, 12-wks, 24-wks"
      },
      {
        "measure": "Symptom-Limited TMT Maximum Oxygen Uptake (VO2)",
        "description": "Peak Oxygen uptake achieved while undergoing a modified Bruce Protocol treadmill test (TMT)",
        "timeFrame": "Baseline, 12-wks, 24-wks"
      },
      {
        "measure": "Maximum Respiratory Exchange Ratio (RER) During TMT",
        "description": "Peak RER achieved while undergoing a modified Bruce Protocol treadmill test (TMT). This is a mathematical ratio of maximally achieved (peak) VCO2 divided by maximally achieved (peak) VO2.",
        "timeFrame": "Baseline, 12-wks, 24-wks"
      },
      {
        "measure": "Symptom-Limited TMT Maximum Carbon Dioxide Expelled (VCO2)",
        "description": "Peak Carbon Dioxide expelled achieved while undergoing a modified Bruce Protocol treadmill test (TMT)",
        "timeFrame": "Baseline, 12-wks, 24-wks"
      },
      {
        "measure": "Symptom-Limited TMT Maximum METS Achieved (MET)",
        "description": "Peak metabolic rate equivalents (METS) achieved while undergoing a modified Bruce Protocol treadmill test (TMT). One MET is defined as the metabolic rate observed at rest, quantified as resting oxygen consumption of 250 ml/min (Male) or 200 ml /min (female). A value of 5 METS would represent a metabolic rate that is 5x that at rest and is considered an indicator of how hard a given individual is exercising. Data shown are expressed as a ratio at peak of exercise of oxygen consumed relative to normalized values for men or women at rest.",
        "timeFrame": "Baseline, 12-wks, 24-wks"
      },
      {
        "measure": "Short Form-36V: Mental Component Score",
        "description": "The short form-36Veterans (SF-36V) health survey questionnaire was used to measure health-related quality of life. This survey is comprised of eight subscales and two overall component scores, all of which have demonstrated high levels of internal consistency and discriminate validity when administered to groups of medically stable individuals. Patient aggregate responses for the eight distinct summary subscales and two component scores were compiled as a percentage of total points possible using the RAND 36-item health survey table. Data shown are expressed as a percentage of total possible score ranging from 0%-100% with 100% considered relatively good health and 0% considered poor health. Mental Component scores reflect perceived changes in emotional health relative to the previous year.",
        "timeFrame": "initial entry into study, and at 12-wks and 24-wks"
      }
    ],
    "other": [
      {
        "measure": "Height",
        "description": "Height of subjects upon entry into study",
        "timeFrame": "baseline"
      },
      {
        "measure": "Weight",
        "description": "Weight of subjects at baseline, 12-weeks, and 24-weeks",
        "timeFrame": "Baseline, 12-wks, 24-wks"
      },
      {
        "measure": "Body Mass Index (BMI)",
        "description": "BMI is calculated as a ratio of subject body mass (kg) divided by the square of subject height (m).",
        "timeFrame": "Baseline, 12-wk, 24-wk"
      },
      {
        "measure": "Duration of Diabetes Mellitus",
        "description": "Duration, in years, since first diagnosed with Diabetes Mellitus upon entry into study",
        "timeFrame": "Baseline"
      },
      {
        "measure": "HbA1C Laboratory Values",
        "description": "Laboratory values of subject HbA1C levels at Baseline, 12-wk, 24-wk",
        "timeFrame": "Baseline, 12-wk, 24-wk"
      },
      {
        "measure": "Triglyceride Laboratory Values",
        "description": "Laboratory triglyceride values at baseline entry into study",
        "timeFrame": "Baseline"
      },
      {
        "measure": "Cholesterol Laboratory Values",
        "description": "Laboratory total cholesterol, HDL-cholesterol, and LDL-cholesterol levels at baseline entry into study",
        "timeFrame": "Baseline"
      },
      {
        "measure": "Creatinine Laboratory Values",
        "description": "Laboratory creatinine values at baseline entry into study",
        "timeFrame": "Baseline"
      },
      {
        "measure": "Blood Urea Nitrogen (BUN) Laboratory Values",
        "description": "Laboratory Blood Urea Nitrogen levels at baseline entry into study",
        "timeFrame": "Baseline"
      },
      {
        "measure": "Aspartate Aminotransferase Laboratory Values",
        "description": "Laboratory values for Aspartate Aminotransferase (AST) at baseline entry into study",
        "timeFrame": "Baseline"
      },
      {
        "measure": "Thyroid Stimulating Hormone Laboratory Values",
        "description": "Laboratory values for Thyroid Stimulating Hormone (TSH) at baseline entry into study",
        "timeFrame": "Baseline"
      },
      {
        "measure": "Age",
        "description": "Age of participants at entry into study.",
        "timeFrame": "at baseline"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 15,
      "secondaryCount": 11,
      "otherCount": 12,
      "totalCount": 38
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "FACTORIAL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:10.167Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}